AbbVie Inc ABBV

Morningstar Rating
€266.10 −4.30 (1.59%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ABBV is trading at a LOCK|@Hw?^# premium.
Price
€266.10
Fair Value
LOCK|f.<pL?#yf
Uncertainty
LOCK|?w&??
1-Star Price
LOCK|&.K&y!g>
5-Star Price
LOCK|J.Bf#@D
Economic Moat
LOCK|V@#
Capital Allocation
—

News

Trading Information

Previous Close Price
€270.40
Day Range
€265.90–268.20
52-Week Range
€164.30–272.30
Bid/Ask
€0.00 / €0.00
Shares Outstanding
1.77B
Market Cap
€470.36B
Volume/Avg
— / 1

Key Statistics

Price/Earnings (Normalized)
35.05
Price/Sales
8.30
Dividend Yield (Trailing)
2.26%
Dividend Yield (Forward)
2.26%
Dividend Payment Schedule
Feb, May, Aug, Nov
Total Yield
2.54%

Company Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
57,000

Competitors

Valuation

Metric
ABBV
MRK
LLY
Price/Earnings (Normalized)
35.05106.5144.31
Price/Book Value
—7.8831.33
Price/Sales
8.305.2714.66
Price/Cash Flow
23.3216.0234.99
Price/Earnings
ABBV
MRK
LLY

Financial Strength

Metric
ABBV
MRK
LLY
Quick Ratio
0.560.780.64
Current Ratio
0.871.351.39
Interest Coverage
5.203.3333.96
Quick Ratio
ABBV
MRK
LLY

Profitability

Metric
ABBV
MRK
LLY
Return on Assets (Normalized)
16.61%2.53%22.55%
Return on Equity (Normalized)
—7.02%91.88%
Return on Invested Capital (Normalized)
36.97%4.79%37.89%
Return on Assets
ABBV
MRK
LLY

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|S%tgprG^LOCK|<g$1T
Johnson & Johnson
JNJ
LOCK|%$@c$&LOCK|qvM$671B
AbbVie Inc
ABBV
LOCK|C@<XJ&QLOCK|s@t$518B
Roche Holding AG ADR
RHHBY
LOCK|<nK<k<nRLOCK|?!$386B
Merck & Co Inc
MRK
LOCK|>vM!^TLOCK|<v$353B
Novartis AG ADR
NVS
LOCK|dM#!%h@<LOCK|D^r$300B
AstraZeneca PLC
AZN
LOCK|CW@yK%vQLOCK|s?#$282B
Amgen Inc
AMGN
LOCK|%%j>xrgLOCK|&j?$248B
Gilead Sciences Inc
GILD
LOCK|XDM!HNLOCK|>$$211B
Novo Nordisk AS ADR
NVO
LOCK|mM$?$nvLOCK|G%$179B

Sponsor Center